This article is more than 5 years old. Information may no longer be current.
Incidence of ocular hypertension after anti-VEGF injections low
Click Here to Manage Email Alerts
After intravitreal anti-VEGF injections, the incidence of delayed ocular hypertension was low in patients with exudative age-related macular degeneration, according to a study.
A retrospective chart review analyzed 302 eyes treated for AMD, of which 32 also had glaucoma. A control group contained 226 untreated fellow eyes, of which 31 also had glaucoma. None of the eyes had baseline ocular hypertension (OHT).
All patients received at least one intravitreal anti-VEGF injection before the start of the study. Delayed OHT was defined as either a single IOP elevation greater than 26 mm Hg with concomitant initiation or augmentation of IOP-lowering therapy or IOP of 22 mm Hg or higher at two consecutive visits with an increase from baseline of more than 6 mm Hg.
In eyes without glaucoma, three injected eyes and four control eyes developed delayed OHT. In eyes with glaucoma, two injected eyes and three control eyes developed delayed OHT. Neither difference was statistically significant.
The development of delayed OHT did not differ between eyes injected with Avastin (bevacizumab, Genentech) only vs. eyes injected with Lucentis (ranibizumab, Genentech) only; the rate of delayed OHT also did not differ between eyes with or without glaucoma.
“The findings in the present study suggest that exudative AMD patients with glaucoma treated with anti-VEGF injections do not have an increased risk of developing delayed OHT compared to patients with glaucoma who are not treated with anti-VEGF injections,” the study authors said.
Click Here to Manage Email Alerts